Recursion Pharmaceuticals, Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was License And Service at $18.1 million, 97% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
68
|
19
|
8
|
6
|
36
|
5
|
19
|
15
|
5
|
| License And Service |
67
+54.3%
share 98.2%
|
18
+262.3%
share 97.3%
|
7
-61.8%
share 95.2%
|
6
-57.5%
share 97.4%
|
35
+683.7%
share 99.5%
|
5
share 96.3%
|
19
share 99.4%
|
15
share 100.5%
|
5
share 99.2%
|
| Grant |
1
+347.6%
share 1.8%
|
0
+158.9%
share 2.7%
|
0
+205.8%
share 4.8%
|
0
+334.2%
share 2.6%
|
0
+434.3%
share 0.5%
|
0
share 3.7%
|
0
share 0.6%
|
-0
share -0.5%
|
0
share 0.8%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RXRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1601830
- Former names
- Recursion Pharmaceuticals, LLC (until Dec 4, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.